INDEPENDENT NEWS

Drug boosts survival for diabetes after pancreatitis

Published: Fri 23 Aug 2019 08:53 AM
A University of Auckland-led study has shown for the first time that diabetes drug metformin halves the risk of death in people with the second most common form of adult-onset diabetes.
Lesser known than its cousins, types 1 and 2 diabetes, ‘diabetes of the exocrine pancreas’ is a form of diabetes caused by the part of the pancreas that produces digestive enzymes. Common contributing causes are pancreatic cancer and pancreatitis, an excruciating inflammation of the pancreas.
This form of diabetes affects at least 10,000 people in Aotearoa New Zealand. People with this form are known to die earlier than those with type 2 diabetes, yet there are no established treatment guidelines and researchers say the condition is under-recognised by doctors.
In the first study of its kind, the University of Auckland’s COSMOS team gathered New Zealand-wide pharmaceutical dispensing data from 2006-2015 and linked it anonymously to the hospital records of 1,862 people with diabetes of the exocrine pancreas.
They found that, in patients with diabetes after pancreatitis (postpancreatitis diabetes), the use of metformin reduced the risk of death by 49 percent compared with patients who had never taken any diabetes drugs. This survival benefit of metformin was even more pronounced than in patients with type 2 diabetes (whose risk of death was reduced by 25 percent). However, in patients with diabetes related to pancreatic cancer, metformin did not boost survival odds.
The results are published in Diabetes Care, the world’s top clinical diabetes journal and the official journal of the American Diabetes Association.
“Strikingly, almost a third - 31 percent - of the people whose records we looked at did not receive any diabetes drug,” says lead author Dr Jaelim Cho, a PhD student in the COSMOS group at the University’s Faculty of Medical and Health Sciences. “It is expected that this population will benefit from metformin use.”
Senior author and principal investigator of the COSMOS group, Associate Professor Max Petrov, says: “Metformin, which is a long-used type 2 diabetes medication that is not expensive and easily available, should now be recommended as the front-line treatment in patients with post-pancreatitis diabetes. For patients with pancreatic cancer-related diabetes, we need more investigations on how to best treat this condition.”
Previous research from the COSMOS group showed that Māori and Pacific adults are at more than double the risk of developing post-pancreatitis diabetes than New Zealand Europeans.
Diabetes Care: Antidiabetic medications and mortality risk in individuals with pancreatic cancer-related diabetes and postpancreatitis diabetes: a nationwide cohort study
ends

Next in Business, Science, and Tech

The Narrow Divide: New Poll Shows Tight Political Race For SME Votes
By: MYOB
Further Easing In Monetary Policy Delivered
By: Reserve Bank
Post-lockdown Retail Card Spending Picks Up
By: Statistics New Zealand
Contact delivers for customers, employees and shareholders
By: Contact Energy
OceanaGold Announces Receipt Of WKP Mining Permit
By: OceanaGold
COVID-19 lockdown has widespread effects on labour market
By: Statistics New Zealand
New Research By NZ Post Shows Online Shopping Grew 105% In Alert Level 3
By: New Zealand Post
Ice-olation For Antarctica New Zealand
By: Antarctica New Zealand
July House Price Index illustrates market resilience
By: QV Valuations
Queenstown Rents Experience Biggest Drop In Seven Years
By: Trade Me Property
The Quiet Earth
By: Auckland University
James Shaw says Kiwibank, not ministers should decide on investors
By: RNZ
Kiwis Confident Financial Markets Will Recover From COVID-19, Plan To Increase Investments
By: Financial Markets Authority
Warehouse Using Covid For Cover As Extensive Restructure Makes Everyone Worse Off
By: FIRST Union
Stronger Green Voice Needed Next Term To Stop More Mining On Or Under Conservation Land
By: Green Party
View as: DESKTOP | MOBILE © Scoop Media